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 Do n-3 fatty acid supplements effect depressive symptoms post cardiovascular event in 
men and women ages 40 and older?	  	  	  	  	  	  	  	  	  Lindsey	  G.	  Caton,	  PA-­‐S	  	  A	  SELECTIVE	  EVIDENCE	  BASED	  MEDICINE	  REVIEW	  	  In	  Partial	  Fulfillment	  of	  the	  Requirements	  For	  	  The	  Degree	  of	  Master	  of	  Science	  	  In	  	  Health	  Sciences-­‐Physician	  Assistant	  	  Department	  of	  Physician	  Assistant	  Studies	  Philadelphia	  College	  of	  Osteopathic	  Medicine	  Philadelphia,	  Pennsylvania	  	  December	  20,	  2013	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
OBJECTIVE:	  The	  objective	  of	  this	  selective	  EBM	  review	  is	  to	  determine	  whether	  or	  not	  n-­‐3	  fatty	  acids	  have	  an	  effect	  on	  depressive	  symptoms	  post	  cardiovascular	  event	  in	  men	  and	  women	  ages	  40	  and	  older.	  Study	  design:	  Systematic	  review	  of	  three	  English	  language	  random	  controlled	  trials	  published	  between	  2011-­‐2012.	  	  	  DATA	  SOURCES:	  Two	  randomized	  controlled	  trials	  published	  after	  2011	  comparing	  the	  effects	  of	  n-­‐3	  fatty	  acid	  supplementation	  on	  depressive	  symptoms	  post	  cardiovascular	  event	  and	  one	  randomized	  controlled	  trial	  comparing	  n-­‐3	  fatty	  acid	  supplementation	  effects	  on	  depressive	  symptoms	  in	  elderly	  patients	  with	  diagnosed	  depression.	  The	  studies	  were	  obtained	  using	  the	  PubMed	  database.	  	  OUTCOMES	  MEASURED:	  Depressive	  symptoms,	  assessed	  using	  the	  Geriatric	  Depression	  Scale,	  was	  the	  primary	  outcome	  measured	  in	  all	  three	  studies.	  In	  all	  studies	  patients	  depressive	  symptoms	  were	  measured	  with	  the	  GDS-­‐15	  before	  the	  trial	  of	  supplementation	  vs.	  placebo	  began,	  and	  then	  after	  the	  trial	  was	  over.	  	  Results	  were	  then	  compared	  before	  and	  after	  supplementation.	  	  RESULTS:	  The	  results	  of	  these	  studies	  show	  an	  insignificant	  decrease	  in	  depressive	  symptoms	  of	  patients	  supplemented	  with	  n-­‐3	  fatty	  acids	  post	  cardiovascular	  event	  vs.	  a	  placebo.	  However,	  one	  study	  showed	  the	  potential	  for	  n-­‐3	  fatty	  acid	  supplementation	  in	  depressed	  elderly	  patients	  unrelated	  to	  cardiovascular	  events	  with	  a	  decrease	  in	  depressive	  symptoms	  after	  supplementation.6	  One	  subgroup	  in	  the	  study	  by	  Andreeva	  and	  colleagues	  reported	  an	  increase	  in	  depressive	  symptoms	  in	  men	  who	  were	  supplemented	  n-­‐3	  fatty	  acids	  for	  the	  trial.4	  	  	  CONCLUSIONS:	  Based	  on	  these	  studies,	  the	  use	  of	  n-­‐3	  fatty	  acids	  for	  decreasing	  depressive	  symptoms	  in	  post-­‐cardiovascular	  events	  can	  not	  be	  justified.	  	  Andreeva	  and	  colleagues,	  as	  well	  as	  Giltay	  and	  colleagues,	  both	  showed	  no	  significant	  difference	  in	  depressive	  symptoms	  in	  patients	  post-­‐cardiovascular	  event	  supplemented	  with	  n-­‐3	  fatty	  acids	  assessed	  by	  the	  GDS-­‐15.4,5	  	  However,	  Tajalizadekhoob	  et	  al.	  showed	  n-­‐3	  fatty	  acid	  supplementation	  in	  elderly	  patients	  with	  diagnosed	  depression	  does	  in	  fact	  improve	  their	  depressive	  symptoms	  with	  a	  NNT	  of	  8.	  6	  Although	  the	  total	  patient	  number	  of	  this	  study	  was	  small,	  further	  investigation	  should	  continue	  as	  this	  proves	  there	  is	  lead	  way	  for	  the	  use	  of	  n-­‐3	  fatty	  acids	  for	  their	  effect	  in	  depression.	  	  Key	  Words:	  Post-­‐cardiovascular	  event,	  Depression,	  Omega-­‐3	  Fatty	  Acids	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INTRODUCTION	  	   Cardiovascular	  disease	  is	  a	  serious	  and	  common	  medical	  condition	  associated	  with	  a	  wide	  range	  of	  symptoms	  including	  chest	  pain,	  diaphoresis,	  and	  nausea.	  	  Cardiovascular	  events	  can	  be	  categorized	  into	  NSTEMI/Unstable	  angina	  and	  STEMI.	  	  Both	  are	  caused	  by	  narrowing	  or	  occlusion	  in	  the	  coronary	  artery	  system	  that	  leads	  to	  decreased	  perfusion	  to	  the	  myocardium.	  	  Ultimately	  the	  decreased	  perfusion	  results	  in	  ischemia	  which	  can	  be	  fatal. 1  Recent studies have 
shown a number of patients who have experienced a cardiovascular event, described 
above, have an increase in depression following.  This paper evaluates randomized 
controlled trials comparing the efficacy of fatty acid supplementation on depressive 
symptoms in patients >40 years old who have experienced a cardiac event. 
 This topic is relevant to both patients and the PA practice due to its commonality.  
Heart disease is a major cause of disability and the leading cause of death in the United 
states for both men and women.  Each year around 715,000 Americans have a heart 
attack.  Of these Americans, the incidence of first heart attacks include 525,000 and the 
incidence of second heart attacks includes 190,000.  The morbidity of heart disease 
counts for 26.5 million people of noninstitutionalized adults.  This makes up about 11.5% 
of all noninstitutionalized adults in the US today.2 
 The most common type of heart disease is coronary heart disease.  The total cost 
of this disease alone is around 108.9 billion dollars per year in the United States.  This 
cost includes health care services, medication and lost productivity.  The American Heart 
Association published an article in 2011 that projected future costs for cardiovascular 
disease to be 444 billion dollars.  With strokes, heart disease is the most costly health 
problem our nation faces today.2  Each year the number of visits to physician offices with 
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heart disease as a primary diagnosis includes 12.4 million people, this excludes ischemic 
heart disease.  The number of patients discharged from inpatient facilities with heart 
disease as first-list diagnosis is around 3.7 million.2 
 The exact incidence of patients with heart disease who experience depressive 
symptoms after a cardiac event is unknown.  Studies have shown up to 33 percent of 
heart attack patients develop some degree of depression.  Depression not only is a 
psychological problem, but can also lead to worsening physical problems.  Patients with 
depression are less likely to take care of their physical health and cut back on rehab 
and/or medication.3 
 Cardiovascular disease treatment involves decreasing risk factors that may cause 
an event such as HTN, Hyperlipidemia, Hypercholesterolemia, and Obesity.  This usually 
begins with lifestyle changes including a low-fat, low-sodium diet, 30-minutes of 
moderate exercise most week days, smoking cessation and limited alcohol intake. 
Additional treatment modalities include a long line of medications used to treat specific 
risk factors including anti-hypertensive medications: diuretics, ACE-inhibitors or beta-
blockers; blood thinners: Aspirin, warfarin, heparin, tPA;  and cholesterol-lowering 
medications: statins or fibrates.  Medical procedures are used in severe life threatening 
situations including coronary angioplasty, coronary artery bypass grafting (CABG) and 
heart transplant.1 
 As stated previously, recent studies have shown a link to depressive symptoms 
and post-cardiac events.  All methods above used to treat cardiovascular disease focus 
solely on the physical symptoms these patients experience and disregard any 
psychological associations.  It is proposed that n-3 fatty acid supplementation may be 
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used to prevent or decrease depressive symptoms in patients who have previously 
experienced a cardiac event. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not n-3 
fatty acid supplements effect depressive symptoms post-cardiovascular event in men and 
women ages 40 and older.  
METHODS 
 Criteria used for selection of studies included patients greater than 40 years old 
who had experienced a cardiovascular event and an intervention of n-3 fatty acid 
supplementation.  This population was compared to an experimental group who received 
a visually matched placebo.  Criteria used for selection of a third study included elderly 
patients with diagnosed depression and an intervention of n-3 fatty acid supplementation. 
The outcomes measured in all studies were the patients depressive symptoms. The types 
of studies included three randomized, double blind, placebo controlled clinical trials. 
 All articles were published in English in peer reviewed journals and searched for 
using key words such as post-cardiovascular event, depressive symptoms and n-3 fatty 
acids.  The three studies in this review were searched using PubMed and selected by 
relevance to the question at hand and standards set forth by the syllabus (POEMs).  
Inclusion criteria for the data sources were randomized, controlled and double blinded 
studies.  Exclusion criteria in all studies were patients under the age of 40 years old.  
Statistics used by the studies included adjusted OR, standardized means, RRR, ARR, 
NNT and p-values.  The specific studies demographics and characteristics can be found 
in Table 1. 
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Table 1: Demographics and Characteristics of included studies 
Study Type #Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Andreeva4 
(2012) 
Double 
blind 
RCT 
1,133 45-
85 
Previous MI, 
Unstable 
angina, or 
Ischemic stroke 
within 12 
preceding mo of 
RCT 
Previous 
cardiovascular 
pathology (eg. 
solid cancer 
or leukemia) 
and with 
expected 
survival <5 
yrs 
126 Long-chain n-3 
PUFAs 
supplementation 
(600mg EPA 
and DHA in a 
2:1 ratio) 
Giltay5 
(2011) 
Double 
blind 
RCT 
2037 60-
80 
Previous MI 
within 10 years 
before the study 
MI >10 years 
ago, age <60 
367 n-3 fatty acid 
supplementation 
(400mg 
margarine 
spread EPA-
DHA/day) 
Tajaliza-
dekhoob6 
(2011) 
Double 
blind 
RCT 
66 > 65 Age > 65, no hx 
of end-stage 
diseases or 
unstable 
medical 
condition, no hx 
of seafood 
allergies, no 
consumption of 
fish oil or 
omega-3 
supplementation 
3 mo prior to 
participation, no 
hx of 
psychiatric d/o 
with exception 
of depression or 
anxiety, no dx 
of mental 
retardation 
Hx of 
dementia 
reported 
based on their 
KCF profiles 
or MMSE of 
> 22, 
individuals 
with GDS-15 
scores >11 
indicating 
severe 
depression 
0 1 g of fish oil 
capsule/day 
(cod liver oil, 
glycerol, water 
and fish oil: 
comprised of 
180mg EPA and 
120mg of DHA) 
 
OUTCOMES MEASURED 
 The outcomes measured in this review were depressive symptoms. Two studies 
measured this in patients >40 who experienced a cardiovascular event given n-3 fatty 
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acid supplementation versus a placebo. Another study measured depressive symptoms in 
diagnosed depressed elderly patients who were given n-3 fatty acid supplementation 
versus a placebo.  Depressive symptoms were measured using the Geriatric Depression 
Scale (GDS-15) in all three studies.4,5,6 
RESULTS 
 This review includes two randomized controlled trials comparing n-3 fatty acid 
supplementation effects on depressive symptoms in post-cardiovascular event patients. A 
third randomized controlled trial looks at the effect of n-3 fatty acid supplementation on 
depressive symptoms in elderly patients with diagnosed mild-moderate depression. All 
studies were double-blinded, included visually matched placebo's and performed on 
patients over the age of 40. 
 In the paper by Andreeva and colleagues, n-3 PUFAs were supplemented in 
cardiovascular disease survivors to determine their effect on depressive symptoms. 
Patients excluded were those with previous cardiovascular pathology and those with 
expected survival <5 years to maximize the results by eliminating possible confounding 
factors.   Supplements were given in 2 capsules of 600mg EPA/DHA in a 2:1 ratio, to 
take once daily for 1 year and patients were then re-examined/resupplied at annual follow 
ups. The presence of depressive symptoms were assessed using the GDS-30.  For primary 
analysis, scores <10 were normal and >10 were considered to have depressive symptoms.  
Scores were obtained after a median follow up of 4.7 + 1.9 years. In the full sample there 
was no effect of n-3 PUFAs on depressive symptoms.  This is shown by using results of 
the principal factorial logistic regression models, an adjusted OR value of 1.16 with 95% 
CI: 0.95, 1.141.  However, when looking at men and women separately, men showed a 
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positive association between n-3 PUFAs and mild depressive symptoms (adjusted OR of 
1.28 with a 95% CI: 1.03, 1.61).  A 28% higher risk of having depressive symptoms was 
shown with men who received n-3 PUFA compared with those who did not. A sensitivity 
analysis was also performed to wean out individuals who reported use of antidepressants 
at baseline (50 women, 73 men).  After the factorial logistic regression models were refit 
with the remaining participants (n=1877) the associations for n-3 PUFAs and depressive 
symptoms remained non-significant.4 
 Giltay and colleagues used the "Alpha Omega Trial" for their study where 
patients post-MI were given n-3 fatty acids (400mg margarine spread of EPA-DHA/day) 
versus a matched placebo.  Those supplemented with EPA-DHA and placebo did not 
differ in baseline characteristics. Patients who had a MI over 10 years ago were excluded 
from the study to reinforce the association between the event itself and depressive 
symptoms, rather than possible confounding factors after the event had occurred.  
Patients less than 60 years of age were also excluded. To assess depressive symptoms of 
the patients the GDS-15 was used, a "yes or no" self-administered questionnaire.  
Completion of the questionnaires were done by trained research nurses at home or in the 
hospital or were mailed to the patients and self-completed.  The scores ranged from 0-15 
where higher scores indicate more severe depressive symptoms (> 5: moderate-severe, 
>10: severe). Changes over time in depression from 40 months compared with baseline 
were analyzed using ANCOVA.  All tests were 2-tailed and a p-value <0.05 denoted 
significance. At the 40 month follow up depressive symptoms did not differ from 
baseline between the supplemented and placebo groups.  The standardized mean 
differences in depressive symptoms for EPA-DHA compared with placebo were -0.048 + 
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0.044 with a p value of 0.28.  However, analysis of a small subgroup of 35 patients who 
used antidepressants at baseline showed a beneficial effect with n-3 fatty acid 
supplementation (P=0.04; Table 2).5 
Table 2: Sub-group Analysis of Outcomes in Post-cardiovascular Event Patients 
Supplemented with EPA-DHA by Giltay and colleagues. 
Group Mean difference for EPA-DHA vs. Placebo P-value 
All participants  
(EPA-DHA n= 1007, placebo n=1030) 
-0.048 + 0.044 0.28 
Antidepressant use at baseline 
(Antidepressant n=36, placebo n=1030) 
-0.477+ 0.235 0.04 
 
 In the study by Tajalizadekhoob et al, elderly patients with mild-moderate 
depression were supplemented with 1 gram fish oil capsule (180mg EPA, 120mg DHA) 
per day to determine its effect on their depressive symptoms.  Patients included those 
with mild to moderate depression who scored a 5-11 on the GDS-15.  Those with a 
history of dementia and/or severe depression graded by a GDS-15 score >11 were 
excluded.  Depression was scored before and after supplementation for 6 months using 
the GDS-15 administered by a clinical psychologist who was blind to the drug groups of 
the participants. A > 25% decrease in GDS-15 score was considered an improvement in 
depression.  At the end of the study there was some efficacy in the treatment of mild to 
moderate depression in elderly patients with n-3 FA supplementation. Patients in the fish 
oil group showed a greater decrease in GDS-15 scores at the end of the study.  In the fish 
oil group 40.7% showed improvement (>25% decrease in GDS score) versus 27.6% in 
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the placebo group with a p-value of 0.13. The NNT was 8, therefore one of every 8 
patients will have a decrease in depressive symptoms when supplemented with n-3 FA.6 
Table 3: Analysis of Outcomes and NNT in Patients Supplemented with n-3 FA for 
Improvement in Depression by Tajalizadekhoob et al.  
Number of patients Relative benefit 
increase (RBI) 
Absolute benefit 
increase (ABI) 
Number needed to 
treat (NNT) 
66 41.0% 12.7% 8 
 
DISCUSSION 
 Cardiovascular events have been shown to cause depressive symptoms in up to 
33% of the patients who experience them.3  With cardiovascular disease as a leading 
cause of morbidity and mortality in the US it is important to address further problems it 
may bring forth.  Although there are many medications used for the treatment of 
depression it is difficult for patients to find a suitable match.  Many anti-depressants 
come with a wide array of side effects and black box warnings, making them undesirable 
to a large population. 
 An alternative treatment for depression that has been recently discussed in the 
literature is the use of n-3 fatty acids.3 Omega-3 fatty acids include alpha-linolenic acid 
(ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  They are 
essential fatty acids, thus can not be made by the human body but can be found in fish, 
algae, some plans and nut oils. Already known to be beneficial in heart disease for their 
decreasing effects on inflammation in the body, scientists now further look at their 
benefits on other psychophysiological processes.7 
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 With their mild side effect profile for most patients, such as gas and diarrhea, the 
omega-3 fatty acids have been a great contender for randomized controlled trials to 
determine their efficacy. Although tolerated by many, it is important to note the more 
serious precautions one must take when considering supplementation. This includes 
blood thinning actions, possible harmful additives, and the possibility to increase fasting 
blood sugar levels (caution with diabetic medication).7 Omega-3 fatty acids are available 
over the counter. 
 The omega-3 fatty acids are a critical component in the structure of the CNS 
membrane.  With alterations in the membrane lipids comes alterations in their fluidity, 
leading to a change in function in receptors, enzymes and transporters.  For these reasons 
and many more omega-3 fatty acids have been implicated to have an effect on 
depression.  Some studies have shown patients with depression to have lower levels of 
fatty acids in their plasma.7 This potential use was indicated in the study by Tajalizadekhoob	  et	  al.	  that	  demonstrated	  a	  decrease	  in	  depressive	  symptoms	  in	  elderly	  patients	  with	  diagnosed	  mild-­‐moderate	  depression	  after	  the	  supplementation	  of	  n-­‐3	  fatty	  acids.6	  	   However,	  limitations	  exist	  with	  this	  study	  by	  Tajalizadekhoob	  that	  hinders	  the	  expansion	  of	  the	  results.	  The population size selected was very small, including only 66 
participants. The results for this study showed a NNT of 8, therefore for every 8 patients 
treated only one showed benefit.6 That is, roughly only 12% showed improvement in this 
study. Another important limiting factor in this study is the season it was done in.  The 
decrease in GDS-15 scores may be seasonally related since it started at the beginning of 
winter when depression is commonly more severe and concluded at the end of spring. 
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 After further research of the expansion of this topic into the use of n-3 fatty acids 
for depression in post-cardiovascular patients, this review does not support its use. Both 
studies done in patients after experiencing a cardiovascular event showed no significant 
improvement in depressive symptoms after supplementation with n-3 fatty acids.4,5  
When Giltay and colleagues analyzed the subset group of those who took anti-
depressants at baseline (Table 2), there was a minor improvement in depressive 
symptoms. This is a possible area for further investigation. For both of these studies 
sample size and duration of the study were sufficient for credibility.  
 Andreeva and colleagues had limitations that arose after they eliminated patients 
due to missing GDS scores.  Because of the missing scores, by chance those still included 
in the trial were more likely to be retired, less likely to smoke and had somewhat lower 
homocysteine levels and higher n-3 PUFA concentrations.  With already higher n-3 
PUFA concentrations there is less room for an increased concentration to play a 
significant effect.4  The major limitation with the study performed by Giltay and 
colleagues was that some patients did not complete the questionnaires at the 40 month 
follow up, all for various reasons.5  
CONCLUSION 
 This review does not support the use of n-3 fatty acid supplementation for 
depressive symptoms in adults 40 years and older post-cardiovascular event.  Not only 
did two studies show no benefit in depressive symptoms, but one in fact showed an 
increase in depressive symptoms.  When Andreeva and colleagues further analyzed their 
studies and looked at just the experimental men group, an increase in depressive 
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symptoms was shown.  This subset of information should be further studied to delineate 
the exact cause by looking at the patients included and possible confounding factors. 
 The potential possibilities why these studies did not show an improvement in 
depressive symptoms after cardiovascular event are wide and unlimited.  With reasonable 
trial time and population selection, one must extend the evaluation of the failure of these 
trials to a deeper cause.  One potential cause may be due to the pathophysiology behind 
depression associated with cardiovascular events that is still not fully understood.  
Perhaps in the future with a better understanding of the pathophysiology, further studies 
will be warranted to better treat depression in post-cardiovascular event patients.   
	  
References:	  
1. Staff, M. (2013, January). Heart Disease. Mayo Clinic. Retrieved September 28, 2013, 
from http://www.mayoclinic.com/health/heart-disease/DS01120/DSECTION=treatments-
and-drugs 
 
2. Heart Disease Facts and Statistics. (2012, October 16). Centers for Disease Control 
and Prevention. Retrieved September 28, 2013, from 
http://www.cdc.gov/heartdisease/statistics.htm 
 
3. Depression and Heart Disease. (2012). American Heart Association. Retrieved 
September 28, 2013, from 
http://www.heart.org/HEARTORG/Conditions/More/MyHeartandStrokeNews/Depressio
n-and-Heart-Health_UCM_440444_Article.jsp 
 
4. Andreeva VA, Galan P, Torres M, Julia C, Hercberg S, Kesse-Guyot E. 
Supplementation with B vitamins or n-3 fatty acids and depressive symptoms in 
cardiovascular disease survivors: Ancillary findings from the SUpplementation with 
FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty acids (SU.FOL.OM3) randomized 
trial. Am J Clin Nutr. 2012;96(1):208-214. doi: 10.3945/ajcn.112.035253; 
10.3945/ajcn.112.035253. 
5. Giltay EJ, Geleijnse JM, Kromhout D. Effects of n-3 fatty acids on depressive 
symptoms and dispositional optimism after myocardial infarction. Am J Clin Nutr. 
2011;94(6):1442-1450. doi: 10.3945/ajcn.111.018259; 10.3945/ajcn.111.018259. 
6. Tajalizadekhoob Y, Sharifi F, Fakhrzadeh H, et al. The effect of low-dose omega 3 
fatty acids on the treatment of mild to moderate depression in the elderly: A double-blind, 
randomized, placebo-controlled study. Eur Arch Psychiatry Clin Neurosci. 
2011;261(8):539-549. doi: 10.1007/s00406-011-0191-9; 10.1007/s00406-011-0191-9. 	  7.	  Painter,	  Frank	  D.C.	  (n.d.).	  	  Neurobehavioral	  Aspects	  of	  Omega-­‐3	  Fatty	  Acids:	  Possible	  Mechanisms	  and	  Therapeutic	  Value	  in	  Major	  Depression.	  The	  Chiropractic	  
Resource	  Organization.	  Retrieved	  December	  9,	  2013,	  from	  http://www.chiro.org/nutrition/ABSTRACTS/Neurobehavioral_Aspects_of_Omega-­‐3.shtml	  	  	  
